Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 61, Issue 10, 2007, Pages 1756-1765

  Torres, F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FLUSHING; FOOD AND DRUG ADMINISTRATION; HAND PARESTHESIA; HEART LEFT VENTRICLE FAILURE; HUMAN; META ANALYSIS; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 34548613383     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01545.x     Document Type: Review

References (28)

1. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991 115 : 343 9.
2. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 353 : 2148 57.
3. Sastry BK, Narasimhan C, Reddy NK et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004 43 : 1149 53.
4. Wilkins MR, Paul GA, Strange JW et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005 171 : 1292 7.
5. Singh TP, Rohit M, Grover A et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006 151 : 851.e1-5.
6. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 358 : 1119 23.
7. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 346 : 896 903.
8. Galie N, Beghetti M, Gatzoulis MA et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006 114 : 48 54.
9. Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004 24 : 353 9.
10. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 174 : 1257 63.
11. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 169 : 441 7.
12. Barst RJ, Langleben D, Badesch DB et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006 47 : 2049 56.
13. Pulido T, Kurzyna M, Souza R et al. Sitaxsentan 100 mg Proves more Effective than Sitaxsentan 50 mg in Patients with Pulmonary Arterial Hypertension (PAH). San Diego, CA : American Thoracic Society, 2006.
14. Galie N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005 46 : 529 35.
15. Oudiz RJ, Torres F, Frost AE et al. ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Chest 2006 130 : 121S (Abstract).
16. Olschewski H, Galie N, Kramer M et al. Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study. San Diego, CA : American Thoracic Society, 2006.
17. Sitbon O, Badesch DB, Channick RN et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003 124 : 247 54.
18. Badesch DB, Rubin LJ. Maintenance of Improvement in 6-Minute Walk Distance with Long Term Bosentan Treatment: Results of the BREATHE-1 Open-label Extension Study. Chicago, IL : American Heart Association, 2006.
19. Rubin LJ, Burgess G, Parpia T et al. Effects of Sildenafil on 6-Minute Walk Distance (6MWD) and WHO Functional Class (FC) after 1 Year of Treatment. San Diego, CA : American Thoracic Society, 2005.
20. Benza R, Frost A, Girgis RE et al. Chronic Treatment of Pulmonary Arterial Hypertension (PAH) with Sitaxsentan and Bosentan. San Diego, CA : American Thoracic Society, 2006.
21. Galie N, Keogh A, Frost A et al. Ambrisentan Long-term Safety and Efficacy in Pulmonary Arterial Hypertension - One Year Follow-up. San Diego, CA : American Thoracic Society, 2005.
22. Segal ES, Valette C, Oster L et al. Risk management strategies in the postmarketing period: Safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005 28 : 971 80.
23. Paul GA, Gibbs JS, Boobis AR et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005 60 : 107 12.
24. Wittke B, Burgess G, Ng T et al. Mutual Pharmacokinetic Interactions Between Steady-State Bosentan and Sildenafil. San Diego, CA : American Thoracic Society, 2005.
25. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000 102 : 865 70.
26. Souza R, Jardim C, Martins B et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin 2005 21 : 907 11.
27. Hoeper MM, Oudiz RJ, Peacock A et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004 43 : 48S 55S.
28. Torbicki A, Kurzyna M, Kuca P et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003 108 : 844 8.